Results 171 to 180 of about 6,042 (221)

Guselkumab

Reactions Weekly, 2022
  +6 more sources

Guselkumab (Tremfya)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Tremfya be reimbursed by public drug plans for the treatment of active psoriatic arthritis (PsA) if certain conditions are met. Tremfya should only be reimbursed to treat adult patients with active PsA according to the reimbursement criteria used for other biologic disease-modifying antirheumatic drugs (DMARDs) that ...
openaire   +1 more source

Guselkumab

Reactions Weekly, 2023
  +5 more sources

Guselkumab in Behçet's disease

Annals of the Rheumatic Diseases
N ...
Elie E Ghayad, Georgina Maalouf, Arsène Mekinian, Giacomo Emmi, Matheus Vieira, Adrien Mirouse, Anne-Claire Desbois, Alexandre Le Joncour, Fanny Domont, Gaëlle Leroux, Helene Bugaut, Mathieu Vautier, Patrice Cacoub, Stéphane Barete, David Saadoun   +14 more
openaire   +2 more sources

Guselkumab: First Global Approval

Drugs, 2017
Guselkumab (Tremfya™) is a human monoclonal IgG1λ antibody being developed by Janssen Biotech, Inc. that has been approved in the USA as a treatment for moderate-to-severe plaque psoriasis. Guselkumab inhibits the binding of interleukin 23 (IL-23) to its cell surface receptor, disrupting the type 17 helper T cell/IL-17 pathway.
openaire   +2 more sources

Guselkumab (Tremfya)

Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Tremfya be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), if certain conditions are met. Tremfya should only be covered for a patient population similar to that eligible for other advanced therapies for UC (e.g., biologics ...
openaire   +1 more source

Guselkumab

Reactions Weekly, 2021
openaire   +2 more sources

Guselkumab

Reactions Weekly
  +5 more sources